Some previous studies showed that the risk of pancreatitis was higher with anti-CTLA-4 than that with anti-PD-1 or anti-PD-L1 (Su et al., 2018; Bai et al., 2021), while another study found that anti-PD-L1 versus anti-PD-1 or anti-CTLA-4 was associated with a slightly increased connection of pancreatitis (Reese et al., 2020). Here, CTLA4 is linked to pancreatitis.